Physician profile
Claus Spies
NPI 1619952769
$3,504.02
in general payments reported to CMS, 2019-2025
27 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $260 · 2021: $506 · 2022: $602 · 2023: $649 · 2024: $559 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649 · Education: $52.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.92 |
| Education | $52.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $809.41 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $639.04 | 2021-2024 | |
| Fresenius USA Marketing, INC. | $250.23 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Nxstage Medical, INC. | $205.92 | 2022-2025 | Pureflow Sl, Nxstage System One |
| Opko Pharmaceuticals, LLC | $194.82 | 2020-2025 | Rayaldee |
| Amgen INC. | $185.05 | 2020-2025 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $163.21 | 2019-2023 | Jynarque |
| Travere Therapeutics, INC. | $144.03 | 2024 | |
| Vantive US Healthcare LLC | $130.16 | 2025 | Renal - Pd |
| Akebia Therapeutics INC | $126.87 | 2019-2025 | Auryxia, Vafseo |
| Baxter Healthcare | $104.23 | 2022 | |
| Vifor Pharma, INC. | $100.19 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $63.45 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $60.55 | 2020-2024 | Acthar |
| Alnylam Pharmaceuticals INC. | $47.80 | 2021-2023 | Oxlumo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44.17 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $34.15 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.47 | 2025 | Jardiance |
| Ardelyx, INC. | $27.53 | 2024 | Ibsrela |
| Horizon Therapeutics Plc | $26.48 | 2019-2020 | |
| Amarin Pharma, INC. | $23.53 | 2019 | |
| Bard Peripheral Vascular, INC. | $22.64 | 2024 | Wavelinq |
| Glaxosmithkline, LLC. | $20.31 | 2021 | |
| Daiichi Sankyo INC. | $20.13 | 2024 | Injectafer |
| Kyowa Kirin, INC. | $14.48 | 2023 | Crysvita |
| Lundbeck LLC | $13.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claus Spies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.